Equity Overview
Price & Market Data
Price: $4.61
Daily Change: +$0.03 / 0.65%
Range: $4.52 - $4.61
Market Cap: $33,168,332
Volume: 10,440
Performance Metrics
1 Week: 9.13%
1 Month: -20.42%
3 Months: -29.49%
6 Months: -43.50%
1 Year: -44.27%
YTD: -32.97%
Company Details
Employees: 55
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.